Understanding Step Therapy Requirements: What Your Practice Needs to Know in 2026

If you've ever had a patient sitting in your office with a prescription in hand—only to discover the insurance company wants them to "try and fail" on two cheaper drugs first—you already know exactly how frustrating step therapy can be. And honestly? It's not getting simpler. As we head into mid-2026, step therapy protocols are more prevalent than ever, and the requirements are shifting in ways that can trip up even experienced billing teams. Let's break down what's actually happening, why it matters for your patients and your revenue cycle, and what you can do about it.

---

What Step Therapy Actually Is (And Why Insurers Love It)

Step therapy—sometimes called "fail first" protocols—requires patients to try one or more alternative treatments before an insurer will cover the originally prescribed medication. The theory is simple: start with the most cost-effective option and escalate from there. In practice, it often means a patient with rheumatoid arthritis gets pushed toward a generic DMARD before their doctor's preferred biologic gets approved.

From the payer's perspective, step therapy saves money. That part is straightforward. But here's what practices sometimes miss: insurers don't all use the same steps, and they change their protocols regularly. A plan that accepted a single step-through exception in 2024 might require two documented failures by 2026. CVS Caremark, Express Scripts, and OptumRx each have their own formulary management approaches—and commercial plans, Medicare Advantage plans, and Medicaid managed care organizations are all operating under different rulebooks.

The most commonly affected drug classes right now include:

• Biologics and biosimilars (especially TNF inhibitors, IL-inhibitors)


• ADHD medications


• Newer diabetes drugs (GLP-1 receptor agonists continue to be heavily restricted)


• Specialty mental health medications


• Migraine-specific treatments like CGRP antagonists

---

What's Changed Heading Into Mid-2026

There are a few meaningful shifts your team should be aware of.

Biosimilar step therapy is everywhere now. With dozens of biosimilars hitting the market over the past couple of years, many plans have restructured their step protocols to require biosimilar trials before reference biologics will be covered. This is particularly relevant for adalimumab (Humira) and its biosimilar competitors—some plans now require a patient to try a specific biosimilar rather than just any equivalent.

GLP-1 step requirements have tightened. Semaglutide and tirzepatide remain extremely high-demand medications, and payers have responded by adding extra hurdles. Expect documentation requirements that go beyond a simple BMI threshold—many plans now want evidence of prior weight loss attempts, comorbidity documentation, and sometimes even dietary counseling records before they'll approve coverage.

Medicare Advantage step therapy protections are being scrutinized. CMS has been paying closer attention to how MA plans apply step therapy for Part B drugs, and there's been ongoing pressure on plans to comply with existing exceptions processes. That doesn't mean the headaches go away—it means you need to know when to invoke those protections.

One thing I've noticed talking with billing managers: a lot of practices are still treating step therapy as a prior auth problem to solve after the prescription is written. Getting ahead of it during the prescription workflow makes a real difference.

---

The Exceptions Process: Where Most Practices Leave Time and Money on the Table

Here's something important—step therapy exceptions are legally required in most states and under most plan types. You don't just have to accept a step therapy requirement. You can challenge it. But the challenge needs to be done correctly.

A valid exception request generally needs to show at least one of the following:

• The patient already tried and failed the required step therapies (with documentation)


• The required drug is contraindicated or would cause an adverse reaction


• The required drug is clinically inappropriate given the patient's specific condition


• Trying the required therapy would delay necessary care and cause harm

The documentation is everything here. Vague clinical notes won't cut it. You need specific language—dates of prior trials, documented adverse effects, explicit clinical reasoning from the prescribing physician. Insurance companies have reviewers specifically looking for reasons to deny, and if your exception letter sounds generic, it's going to get denied.

Real-world example: A patient with treatment-resistant depression is prescribed a newer atypical antipsychotic as an adjunct therapy. The plan wants them to try two older-generation alternatives first. The prescriber already tried one of those alternatives three years ago under a prior practice—but if that history isn't documented and submitted with the exception request, it's invisible to the reviewer. Outcome: unnecessary delay, frustrated patient, extra work for your staff.

This is actually one area where AI-powered appeal and exception letter generators have become genuinely useful—not as a replacement for clinical judgment, but as a way to ensure the request hits all the required elements and is formatted in a way payers actually respond to.

---

Practical Steps Your Team Can Take Right Now

You don't need to overhaul everything. A few targeted process improvements make a real difference.

Build a step therapy reference into your workflow. Whether it's a shared document, an EHR flag, or a third-party tool, your team should be able to quickly look up a payer's current step requirements before the prescription goes out. Surprises at the pharmacy aren't good for anyone.

Create a documentation template for common step therapy scenarios. If you regularly prescribe biologics, GLP-1s, or specialty psych medications, have a template ready for the most common exception requests. Customize it per patient, obviously—but don't start from scratch every time.

Train front-line staff to recognize step therapy triggers. Not every exception request needs to land on the physician's desk immediately. Medical assistants and prior auth coordinators can gather the preliminary documentation while the prescriber is with other patients.

Track your denials and overturn rates. If you're seeing a pattern of denials on a particular drug or from a particular payer, that's useful data. It tells you where to invest time in better documentation—or where to escalate to the payer's medical director.

Know your state's step therapy laws. Several states have enacted protections that limit how long a step therapy process can take or require expedited exceptions for certain conditions. If you're in New York, Texas, California, or Virginia (among others), there are specific timelines and criteria that payers are legally required to follow.

---

Don't Let Step Therapy Become a Patient Abandonment Problem

Here's the piece that doesn't get talked about enough: when step therapy delays get long, patients give up. They don't fill the prescription, they miss doses on existing therapies, or they go out-of-pocket on a medication they shouldn't have to pay for. That's a clinical problem, not just an administrative one.

Keeping patients informed through the process—letting them know it might take 7-14 days, that you're fighting for their coverage, that there's an exception process in motion—goes a long way. Patient abandonment during prior auth delays is a real and measurable problem, and proactive communication is one of the cheapest ways to address it.

---

Where to Go From Here

Step therapy isn't going away, and the complexity is likely to keep increasing as biosimilar adoption accelerates and payers get more sophisticated about formulary management. The practices that handle this well in 2026 aren't doing magic—they're just more systematic about documentation, more proactive about payer requirements, and more willing to push back through the exceptions process.

If your team is drowning in prior auth and step therapy denials, take a week to audit your most common denial reasons. You'll almost certainly find patterns. Fix the documentation process for those specific scenarios, and you'll see a measurable improvement. That's the unglamorous, unsexy truth of how this actually gets better—one workflow at a time.